In this work, a computational-efficient deep learning architecture AM-Unet is proposed to extract road information from high-resolution aerial imagery. The proposed method alters the design of Unet architecture for the encoder, decoder, and skip connections. These changes enhance the computational ...
Correction: AM-UNet: Road Network Extraction from high-resolution Aerial Imagery Using Attention-Based Convolutional Neural Network doi:10.1007/s12524-025-02156-5Springer IndiaJournal of the Indian Society of Remote SensingYashwant Sonihttps://ror.org/050113w36grid.412742.60000 0004 0635 5080Department...
To this end, we propose SmaAt-UNet, an efficient convolutional neural networks-based on the well known UNet architecture equipped with attention modules and depthwise-separable convolutions. We evaluate our approaches on a real-life datasets using precipitation maps from the region of the Netherlands...
vivian-wong/AM_defects_nnUNetPublic forked fromMIC-DKFZ/nnUNet NotificationsYou must be signed in to change notification settings Fork0 Star0 master 2Branches 2Tags Code Repository files navigation README Apache-2.0 license nnU-Net on AM: ...
mosunetuzumab结构特征 罗氏(Roche)旗下基因泰克(Genentech)近日公布了双特异性抗体mosunetuzumab(CD20xCD3)、glofitamab(CD20xCD3)、cevostamab(FcRH5xCD3)的关键临床数据。结果继续显示,3款双特异性抗体在临床试验中显示出令人鼓舞的...
近日,在第62届美国血液学会(ASH)年会上罗氏(Roche)公布了2款在研T细胞结合CD20xCD3双特异性抗体mosunetuzumab和glofitamab的新数据。结果显示,这2款抗体药物在多种类型血液癌症中表现出令人鼓舞的活性,完全缓解率在50-80%。 在临床试验中,罗氏的这2款CD20xCD3 T细胞结合双特异性抗体mosunetuzumab和glofitamab,在...
@article{gupta2023image, title={Image segmentation keras: Implementation of segnet, fcn, unet, pspnet and other models in keras}, author={Gupta, Divam}, journal={arXiv preprint arXiv:2307.13215}, year={2023} } Getting Started Prerequisites ...
Glofitamab 和Mosunetuzumab 一样,均为CD20 x CD3双特异性抗体,但Glofitamab抗体的Fab段含有2个CD20结合区和1个CD3结合区,2个靶向CD20的Fab区可以结合恶性B细胞表面2个CD20分子,特异性更强。 另外,Glofitamab的Fc区,被设计为取消FcγRs和C1q的结合,同时保持FcRn的结合,这可延长药物的循环半衰期。 2、适应症...
研究性双特异性 glofitamab 在复发或难治性 (R/R) 大 B-细胞淋巴瘤 (LBCL) 表明 glofitamab 有可能成为第一个现成的 CD20xCD3 T 细胞结合双特异性抗体,可以在固定的时间内给予患有严重预处理的侵袭性淋巴瘤的人。这些数据将在会上呈现,并同步在线发布于新英格兰医学杂志 (NEJM)。此外,mosunetuzumab 的...
CD20/CD3双抗Glofitamab(Columvi/Mosunetuzumab)治疗弥漫性大B淋巴瘤的优异数据足以使其加速批准(美FDA)和附条件授权(欧)转为正式批准!III期临床研究STARGLO,Columvi联用吉西他滨+奥沙利铂(简写“GemOx”),对照是美罗华联用GemOx(R-GemOx),治疗复发和难治(R/R)弥漫性大B细胞淋巴瘤(DLBCL),患者不适宜造血...